The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
β1 Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts
Open accessAbstract
β1 Integrin signaling has been shown to mediate cellular resistance to apoptosis after exposure to ionizing radiation (IR). Other signaling molecules that increase resistance include Akt, which promotes cell survival downstream of β1 integrin signaling. We previously showed that β1 integrin inhibitory antibodies (e.g., AIIB2) enhance apoptosis and decrease growth in human breast cancer cells in three-dimensional laminin-rich extracellular matrix (lrECM) cultures and in vivo. Here, we asked whether AIIB2 could synergize with IR to modify Akt-mediated IR resistance. We used three-dimensional lrECM cultures to test the optimal combination of AIIB2 with IR treatment of two breast cancer cell lines, MCF-7 and HMT3522-T4-2, as well as T4-2 myr-Akt breast cancer colonies or HMT3522-S-1, which form normal organotypic structures in three-dimensional lrECM. Colonies were assayed for apoptosis and β1 integrin/Akt signaling pathways were evaluated using Western blot. In addition, mice bearing MCF-7 xenografts were used to validate the findings in three-dimensional lrECM. We report that AIIB2 increased apoptosis optimally post-IR by down-regulating Akt in breast cancer colonies in three-dimensional lrECM. In vivo, addition of AIIB2 after IR significantly enhanced tumor growth inhibition and apoptosis compared with either treatment alone. Remarkably, the degree of tumor growth inhibition using AIIB2 plus 2 Gy radiation was similar to that of 8 Gy alone. We previously showed that AIIB2 had no discernible toxicity in mice; here, its addition allowed for a significant reduction in the IR dose that was necessary to achieve comparable growth inhibition and apoptosis in breast cancer xenografts in vivo. [Cancer Res 2008;68(11):4398–405]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antibodies against integrins β1, β6 and β8 were shown to selectively impair TGF-β1 activation85,313–315”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [315]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
Giancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869
Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.231 · Cited by 1,483
Self-citationWerb, Z., Tremble, P., Behrendtsen, O., Crowley, E., & Damsky, C. H. (1989) · The Journal of Cell Biology · doi:10.1083/jcb.109.2.877 · Cited by 1,057
Damiano, J. S., Cress, A. E., Hazlehurst, L., Shtil, A. A., & Dalton, W. S. (1999) · Blood · doi:10.1182/blood.v93.5.1658 · Cited by 899
Brognard, J., Clark, A. S., Ni, Y., & Dennis, P. A. (2001) · PubMed · Cited by 885
The Akt-mTOR tango and its relevance to cancer
Hay, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.008 · Cited by 826
Weaver, V. M., Lelièvre, S. A., Lakins, J. N., Chrenek, M. A., Jones, J., Giancotti, F. G., Werb, Z., & Bissell, M. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00125-3 · Cited by 794
Self-citationWang, F., Weaver, V. M., Petersen, O. W., Larabell, C. A., Dedhar, S., Briand, P., Lupu, R., & Bissell, M. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14821 · Cited by 653
Self-citationPark, C. C., Mitsumori, M., Nixon, A. J., Recht, A., Connolly, J. L., Gelman, R. S., Silver, B., Hetelekidis, S., Abner, A. L., Harris, J. R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1668 · Cited by 547
Self-citation
Cited by
Sorted by citations
Items 201–220 of 220
Role of extracellular matrix in chordoma progression and therapeutic resistance
Ren, C., Hornicek, F. J., Rosenberg, A. E., Yue, B., & Duan, Z. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105073 · Cited by 1
Targeting Breast Cancer Stem Cells
Pham, P. V. (2015) · SpringerBriefs in stem cells · doi:10.1007/978-3-319-22020-8_6 · Cited by 1
Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance
Akkari, L., & Lujambio, A. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-56197-4_3 · Cited by 1
Basic Principles of Radiobiology and Cancer Metastasis Prevention
Harryman, W. L., & Cress, A. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-93084-4_62 · Cited by 1
Sutherland, R. L. (2008) · Breast Cancer Online · doi:10.1017/s1470903108008432 · Cited by 1
Engineered 3D models to study the cancer microenvironment as a determinant of drug response
Håkanson, M. (2011) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-a-006706762
Shannon, L. A. (2010) · KU ScholarWorks (The University of Kansas)
DeClerck, Y. A. (2014)
Karna, S. K. L., Lone, B. A., Ahmad, F., Shahi, N., & Pokharel, Y. R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.24.963769
Ahmed, K. M. (2014) · Springer eBooks · doi:10.1007/978-3-642-27841-9_7138-4
Mercier, M.-C. (2018) · theses.fr (ABES) · doi:10.70675/273bcce1z8572z472ez9afbzca3fd562301c
Kühnel, F., Ebert, S., Piechota, O., Tellier, L., Meyer, F., Koch, A., Lungu, C., & Olayioye, M. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.22.733747
Echavidre, W., Picco, V., & Montemagno, C. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1930948
Understanding and targeting the tumour matrisome
Pally, D., Englund, J. I., & Naba, A. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01203-5
A Two-Layered Agar Matrix for 3D Cancer Cell Culture in Experimental Radiotherapy
Scholz, M. L., Soloviova, J., Jaekel, F., Kohrer, L., Fiedler, S., Arfelli, F., Menk, R. H., Mewes, C., Klingenberg, J., Faria, G. A., et al. (2026) · Bioengineering · doi:10.3390/bioengineering13111242
Benton, G. (2010) · DigitalGeorgetown (Georgetown University Library)
Metadata
- Authors
- Park, C. C., Zhang, H. J., Yao, E. S., Park, C. J., & Bissell, M. J.
- Affiliations
- University of California, San Francisco (US)
- Lawrence Berkeley National Laboratory (US)
- Venue
- Cancer Research
- Published
- 2008-06-01
- Volume
- 68
- Issue
- 11
- Pages
- 4398-4405
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC3719863
- OpenAlex
- W1968324001
- Cited by
- 220
- References
- 43
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 15 · 2020: 9 · 2019: 10 · 2018: 12 · 2017: 14 · 2016: 13 · 2015: 13 · 2014: 20 · 2013: 19 · 2012: 18
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- U.S. Department of Defense (DE-AC02-05CH11231)
- U.S. Department of Energy (-AC02-05CH11231, DE-AC03-?, AC03-76SF00098, DEAC03-76SF00098, 05CH11231, DE AC02 05CH11231, DE-AC02-)
- National Institutes of Health (DE-AC02–05CH11231, NIH P50, DE-AC03- 76SF00098)
- University of California, San Francisco
- National Cancer Institute (R01CA124891, CA64786-09, CA-58207, R37CA064786, P50CA058207, R01CA064786, CA CA58207-08, DE-AC02-05CH11231)
- Biological and Environmental Research (05CH11231, DE-AC02 − 05CH11231, AC02-05CH11231)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- beta1 integrin, radiotherapy, breast cancer, Akt signaling, radioresistance (biology), apoptosis, MCF-7 xenografts, tumor growth inhibition, radiosensitization
- MeSH terms
- Breast, Breast Neoplasms, Cell Line, Cell Separation, Humans, Transplantation, Heterologous, Blotting, Western, Treatment Outcome, Apoptosis, Microscopy, Confocal, Integrin beta1, In Situ Nick-End Labeling, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
